Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 10:13AM ET
0.7395
Dollar change
+0.0255
Percentage change
3.57
%
IndexRUT P/E- EPS (ttm)-1.72 Insider Own49.93% Shs Outstand93.09M Perf Week5.45%
Market Cap84.35M Forward P/E- EPS next Y-0.45 Insider Trans-0.29% Shs Float57.11M Perf Month2.30%
Income-168.86M PEG- EPS next Q-0.43 Inst Own48.22% Short Float9.66% Perf Quarter-54.63%
Sales0.00M P/S- EPS this Y20.67% Inst Trans25.02% Short Ratio2.51 Perf Half Y-77.39%
Book/sh1.71 P/B0.43 EPS next Y73.96% ROA-62.31% Short Interest5.52M Perf Year-89.04%
Cash/sh1.87 P/C0.40 EPS next 5Y- ROE-75.29% 52W Range0.62 - 6.79 Perf YTD8.78%
Dividend Est.- P/FCF- EPS past 5Y-104.72% ROI-78.45% 52W High-89.11% Beta0.83
Dividend TTM- Quick Ratio6.65 Sales past 5Y-46.37% Gross Margin- 52W Low18.68% ATR (14)0.06
Dividend Ex-Date- Current Ratio6.65 EPS Y/Y TTM38.30% Oper. Margin0.00% RSI (14)48.65 Volatility6.64% 6.89%
Employees106 Debt/Eq0.17 Sales Y/Y TTM- Profit Margin- Recom4.00 Target Price1.00
Option/ShortYes / Yes LT Debt/Eq0.10 EPS Q/Q21.52% Payout- Rel Volume0.36 Prev Close0.71
Sales Surprise- EPS Surprise6.07% Sales Q/Q- EarningsNov 02 BMO Avg Volume2.20M Price0.74
SMA205.47% SMA50-13.56% SMA200-68.52% Trades Volume121,829 Change3.57%
Date Action Analyst Rating Change Price Target Change
Dec-26-23Downgrade BofA Securities Buy → Underperform $17 → $1
Dec-22-23Downgrade Piper Sandler Overweight → Neutral
Dec-22-23Downgrade Leerink Partners Outperform → Market Perform
Dec-22-23Downgrade JP Morgan Overweight → Underweight
Aug-18-23Initiated BofA Securities Buy $17
Oct-19-21Resumed Morgan Stanley Overweight $48
Aug-24-20Initiated SVB Leerink Outperform $41
Aug-24-20Initiated Morgan Stanley Overweight $49
Aug-24-20Initiated JP Morgan Overweight $50
Feb-28-24 01:06AM
Feb-27-24 08:00AM
Feb-26-24 12:27PM
Feb-23-24 10:30AM
Jan-29-24 09:40AM
09:45AM Loading…
Jan-24-24 09:45AM
Jan-12-24 09:35AM
Jan-05-24 11:03AM
08:37AM
Dec-26-23 10:04AM
Dec-22-23 09:31AM
08:30AM
07:10AM
07:00AM
Dec-05-23 08:55AM
07:00AM Loading…
Nov-16-23 07:00AM
Nov-02-23 10:04AM
07:00AM
Sep-21-23 02:44PM
Sep-14-23 09:59AM
Aug-28-23 07:00AM
Aug-03-23 07:00AM
Jul-21-23 07:17AM
Jul-12-23 03:12AM
Jul-04-23 07:34AM
Jul-03-23 03:59AM
Jun-27-23 12:00PM
Jun-23-23 01:56PM
Jun-21-23 09:20PM
04:18PM
11:04AM Loading…
Jun-09-23 11:04AM
Jun-05-23 07:00AM
May-16-23 07:00AM
May-04-23 07:00AM
May-01-23 07:00AM
Apr-26-23 05:12PM
07:00AM
Mar-30-23 11:12AM
Feb-23-23 04:15PM
Feb-15-23 10:05AM
07:07AM
07:00AM
Feb-10-23 09:55AM
Feb-07-23 10:17AM
Feb-01-23 07:00AM
Jan-25-23 12:00PM
09:55AM
09:40AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-10-22 05:15PM
Nov-15-22 07:00AM
Nov-03-22 09:07AM
07:00AM
Oct-21-22 08:30AM
Sep-06-22 09:55AM
Aug-31-22 07:00AM
Aug-19-22 09:55AM
Aug-04-22 07:00AM
Aug-03-22 09:55AM
Aug-01-22 08:09AM
Jul-27-22 07:00AM
Jun-07-22 12:07PM
08:30AM
May-05-22 07:00AM
Apr-21-22 11:35AM
Apr-20-22 07:00AM
Apr-04-22 07:40PM
Mar-31-22 07:00AM
Mar-23-22 09:56AM
Mar-22-22 07:00AM
Feb-11-22 07:00AM
Feb-10-22 07:00AM
Jan-05-22 07:30AM
Jan-03-22 04:05PM
Dec-16-21 04:05PM
Dec-11-21 01:00PM
Nov-17-21 11:57AM
Nov-15-21 07:00AM
Nov-10-21 11:48AM
Nov-05-21 07:00AM
Oct-29-21 09:47AM
Oct-06-21 11:31AM
Oct-05-21 06:48AM
Oct-04-21 07:00AM
Sep-29-21 02:09PM
07:00AM
Sep-07-21 07:00AM
Sep-03-21 08:19AM
Aug-26-21 01:41PM
Aug-06-21 07:00AM
Jun-27-21 03:19AM
May-06-21 07:00AM
Apr-07-21 09:45PM
Mar-29-21 01:17AM
Mar-23-21 08:18AM
Mar-22-21 04:00PM
Feb-17-21 07:30AM
Feb-11-21 04:00PM
07:00AM
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Brainard DianaChief Executive OfficerFeb 21Sale0.715,1553,650814,069Feb 22 04:18 PM
Brainard DianaChief Executive OfficerFeb 20Sale0.703,0972,153819,224Feb 22 04:18 PM
Sinha VikasSee RemarksFeb 20Sale0.702,8932,0111,142,359Feb 22 04:15 PM
Hagen Brett RChief Accounting OfficerFeb 20Sale0.7049434378,853Feb 22 04:15 PM
Miller EdwardGeneral CounselFeb 20Sale0.70385268224,978Feb 22 04:16 PM
Hagen Brett RChief Accounting OfficerFeb 08Sale0.6711,1507,49479,347Feb 09 08:01 PM
Brainard DianaChief Executive OfficerFeb 05Sale0.6741,42127,752822,321Feb 06 04:38 PM
Sinha VikasSee RemarksFeb 05Sale0.6718,33112,2821,145,252Feb 06 04:46 PM
Miller EdwardGeneral CounselFeb 05Sale0.678,8695,942225,363Feb 06 04:40 PM
Hagen Brett RChief Accounting OfficerFeb 05Sale0.675,7923,88190,497Feb 06 04:39 PM
Brainard DianaChief Executive OfficerJan 23Sale0.679,5006,369863,742Jan 25 04:15 PM
Sinha VikasSee RemarksJan 23Sale0.673,2052,1501,163,583Jan 25 04:15 PM
Miller EdwardGeneral CounselJan 23Sale0.671,302873234,232Jan 25 04:15 PM
Hagen Brett RChief Accounting OfficerJan 23Sale0.6790160496,289Jan 25 04:15 PM
Brainard DianaChief Executive OfficerJan 04Sale0.641,6641,063873,242Jan 08 04:15 PM
Sinha VikasSee RemarksJan 04Sale0.649616141,166,788Jan 08 04:15 PM
Miller EdwardGeneral CounselJan 04Sale0.64424271235,534Jan 08 04:15 PM
Hagen Brett RChief Accounting OfficerJan 04Sale0.6431019897,190Jan 08 04:15 PM
Hagen Brett RChief Accounting OfficerDec 27Sale0.7428,33520,83897,500Jan 02 07:36 PM
Brainard DianaChief Executive OfficerNov 20Sale1.694,3827,408874,906Nov 21 05:00 PM
Brainard DianaChief Executive OfficerNov 17Sale1.632,6894,386879,288Nov 21 05:00 PM
Sinha VikasSee RemarksNov 17Sale1.632,4904,0611,167,749Nov 21 05:00 PM
Hagen Brett RChief Accounting OfficerNov 17Sale1.63403657125,835Nov 21 05:00 PM
Sinha VikasSee RemarksOct 20Sale1.541,4752,2731,170,239Oct 23 05:00 PM
Hagen Brett RChief Accounting OfficerOct 20Sale1.54357550126,238Oct 23 05:00 PM
Brainard DianaChief Executive OfficerOct 19Sale1.588,58113,558881,977Oct 23 05:00 PM
Sinha VikasSee RemarksOct 19Sale1.581,2321,9471,171,714Oct 23 05:00 PM
Hagen Brett RChief Accounting OfficerOct 19Sale1.58358566126,595Oct 23 05:00 PM
Brainard DianaChief Executive OfficerOct 03Sale1.981,3252,619890,558Oct 05 05:00 PM
Sinha VikasSee RemarksOct 03Sale1.987551,4921,172,946Oct 05 05:00 PM
Hagen Brett RChief Accounting OfficerOct 03Sale1.98222439126,953Oct 05 05:00 PM
Brainard DianaChief Executive OfficerAug 18Sale2.794,05511,313891,883Aug 21 05:00 PM
Brainard DianaChief Executive OfficerAug 17Sale2.5011,36128,351895,938Aug 21 05:00 PM
Sinha VikasSee RemarksAug 17Sale2.5010,51626,2431,173,701Aug 21 05:00 PM
Hagen Brett RChief Accounting OfficerAug 17Sale2.501,6534,125127,175Aug 21 05:00 PM
Sinha VikasSee RemarksJul 20Sale3.351,4374,8101,184,217Jul 21 05:00 PM
Hagen Brett RChief Accounting OfficerJul 20Sale3.353421,145128,828Jul 21 05:00 PM
Brainard DianaChief Executive OfficerJul 19Sale3.568,34229,710907,299Jul 21 05:00 PM
Sinha VikasSee RemarksJul 19Sale3.561,1984,2671,185,654Jul 21 05:00 PM
Hagen Brett RChief Accounting OfficerJul 19Sale3.563421,218129,170Jul 21 05:00 PM
Brainard DianaChief Executive OfficerJul 05Sale3.055,27516,063915,641Jul 06 05:00 PM
Sinha VikasSee RemarksJul 05Sale3.052,9839,0841,186,852Jul 06 05:00 PM
GILEAD SCIENCES, INC.10% OwnerJun 27Buy3.752,930,87010,990,76216,635,286Jun 28 05:17 PM
Hagen Brett RChief Accounting OfficerJun 09Sale5.645,04528,453129,512Jun 13 05:00 PM
Brainard DianaChief Executive OfficerMay 18Sale4.214,53619,115916,628May 19 05:00 PM
Sinha VikasSee RemarksApr 20Sale3.631,4665,3151,185,055Apr 21 04:05 PM
Hagen Brett RChief Accounting OfficerApr 20Sale3.633491,265134,557Apr 21 04:05 PM
Brainard DianaChief Executive OfficerApr 19Sale3.718,40831,183921,164Apr 21 04:05 PM
Sinha VikasSee RemarksApr 19Sale3.711,2174,5131,186,521Apr 21 04:05 PM
Hagen Brett RChief Accounting OfficerApr 19Sale3.713481,291134,906Apr 21 04:05 PM